7ET,]9-I8N<#K$ZYY4IV%S;>A5$Z8R:E7JBO
SYSTEM PROCESSING...
7ET,]9-I8N<#K$ZYY4IV%S;>A5$Z8R:E7JBO
SYSTEM PROCESSING...
Posted: 2025-04-19 22:09:57 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-19 22:10:33 UTC
Verified By
Rollup News
This content discusses the pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease (MASLD), including genetic and epigenetic factors, cellular interactions, and metabolic pathways involved in the disease progression.
Genetic variants (PNPLA3, TM6SF2, MBOAT7, GCKR, HSD17B13) influence MASLD.
Epigenetic factors like DNA methylation and histone modification play a role.
De Novo Lipogenesis is transcriptionally controlled by SREBP1c and ChREBP.
Lipotoxicity, insulin resistance, and ER stress contribute to MASLD.
The gut-liver axis and hepatic stellate cells are important in fibrosis.
Complex interplay of genetic, epigenetic, and environmental factors in MASLD.
Heterogeneity of T cells in disease progression.
Targeting the gut-liver axis for therapeutic intervention.
Managing lipotoxicity and insulin resistance to prevent fibrosis.